RxDoctor Payments Data

Gabriel Gil, MD

Family Medicine · San Diego, CANPI 1548361587

Payments from drug & device makers

$29,951in general payments, 2019–2025

Across 81 payments — averaging $369.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$28K
  • Novo Nordisk$864
  • Lilly USA, LLC$179
  • GSK$178
  • Johnson & Johnson$118
  • Abbott$41
  • plus $120 from 6 others

What the payments were for

  • Food & beverage$1,49099%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,951 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$68,644
Medicare patients
128
Services billed
580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin100$111,213
OzempicSemaglutide81$83,213
EliquisApixaban59$61,904
JanuviaSitagliptin Phosphate42$45,086
RybelsusSemaglutide21$36,222
FarxigaDapagliflozin Propanediol43$34,581
TrulicityDulaglutide21$25,458
JanumetSitagliptin Phos/Metformin Hcl16$24,505
MounjaroTirzepatide21$21,542
Tresiba Flextouch U-100Insulin Degludec22$15,705
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$12,451
XareltoRivaroxaban11$10,553
Atorvastatin Calcium677$9,017
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$7,992
Combivent RespimatIpratropium/Albuterol Sulfate12$5,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$864$119,435102 claims
Lilly USA, LLCTrulicity, Mounjaro$179$47,00142 claims
AstraZenecaFarxiga, Symbicort$15$38,05658 claims
GSKTrelegy Ellipta$178$12,45121 claims
Johnson & JohnsonXarelto$118$10,55311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →